

**PHARMACORP RX INC.**  
**NOTICE-AND-ACCESS NOTIFICATION TO SHAREHOLDERS**  
**NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS**  
**TO BE HELD ON OCTOBER 8, 2026**

Dear shareholder:

You are receiving this notification because PharmaCorp Rx Inc. (“**PharmaCorp**” or the “**Corporation**”) will be using the notice-and-access model (“**Notice-and-Access**”) provided for under National Instrument 51-102 and National Instrument 54-101 for the delivery of meeting materials to its shareholders in respect of the annual general and special meeting to be held on October 8, 2026 (the “**Meeting**”). Under Notice-and-Access, instead of receiving printed copies of the Corporation’s management information circular (“**Information Circular**”), shareholders receive this notice with information on how to access the Information Circular electronically. However, together with this notice, shareholders continue to receive a proxy or voting instruction form (“**VIF**”), enabling them to vote at the Meeting. Adopting Notice-and-Access to deliver materials is more environmentally friendly as it reduces paper use and also lowers the Corporation’s costs for printing and mailing.

**Meeting Date, Location and Purposes**

The Meeting will be held on **October 8, 2026 at 9:30 a.m. (MST)** in **virtual format** by live webcast online at <https://virtual-meetings.tsxtrust.com/1978> (password: pharmacorp2026) for the following purposes:

1. Report and Financial Statements: to receive and consider the audited financial statements of the Corporation for the financial year ended December 31, 2025, and the report of the auditor thereon, as well as the unaudited interim financial statements for the period ended June 30, 2026. Please refer to “*Report and Financial Statements*” in the Information Circular.
2. Fix Number of Directors to be Elected at the Meeting: to fix the number of directors of the Corporation to be elected at the Meeting at seven (7). Please refer to “*Fix Number of Directors to be Elected at the Meeting*” in the Information Circular.
3. Election of Directors: to elect the Board of Directors of the Corporation for the ensuing year. Please refer to “*Election of Directors*” in the Information Circular.
4. Appointment of Auditor: to appoint the auditor of the Corporation for the ensuing year and to authorize the Board of Directors to fix the auditor’s remuneration. Please refer to “*Appointment of Auditor*” in the Information Circular.
5. Re-approval of Stock Option Plan: to consider, and if thought fit, approve the ordinary resolution, as more particularly set forth in the accompanying Information Circular prepared for the purpose of the Meeting, relating to the re-approval of the stock option plan of the Corporation. Please refer to “*Re-approval of Stock Option Plan*” in the Information Circular.
6. Re-approval of Equity Incentive Plan: to consider, and if thought fit, approve the ordinary resolution, as more particularly set forth in the accompanying Information Circular prepared for the purpose of the Meeting, relating to the re-approval of the equity incentive plan of the Corporation. Please refer to “*Re-approval of Equity Incentive Plan*” in the Information Circular.
7. Other Matters: to transact such other business as may properly come before the Meeting or any adjournment thereof.

For detailed information with respect to each of the above matters, please refer to the subsection bearing the corresponding title under “*Particulars of Matters to be Acted Upon*” in the Information Circular.

**PHARMACORP URGES SHAREHOLDERS TO REVIEW THE INFORMATION CIRCULAR BEFORE VOTING.**

Notice-and-Access is a set of rules intended to reduce the volume of materials that must be physically mailed to shareholders by allowing issuers to post the Information Circular and additional materials online. Materials may be delivered electronically to shareholders. Please call TSX Trust Company (Canada) toll free at 1-866-600-5869 or email [tsxtis@tmx.com](mailto:tsxtis@tmx.com) if you have any questions about Notice-and-Access.

### Accessing Meeting Materials Online

The Meeting materials can be viewed online under PharmaCorp Rx Inc.'s profile at [www.sedarplus.ca](http://www.sedarplus.ca) or at <https://docs.tsxtrust.com/2349>.

### Requesting Printed Meeting Materials

Shareholders can request that printed copies of the Meeting materials be sent to them by postal delivery at **no cost to them** up to one (1) year from the date the Information Circular was filed on SEDAR+. Shareholders may make their request **without charge** by calling the toll-free number at 1-866-600-5869 or 416-316-0930 (outside of Canada and the U.S.) or by sending an email to [tsxtis@tmx.com](mailto:tsxtis@tmx.com). In order to receive paper copies in time to vote before the Meeting, your request should be received by September 24, 2026.

### Voting Process

*Registered holders:* If you are not attending the Meeting, you can submit your proxy as follows:

By Mail: Sign, date and return the enclosed proxy to TSX Trust, Attention: Proxy Department, 301 – 100 Adelaide Street West, Toronto, Ontario M5H 4H1.

By Facsimile: Sign, date and fax the enclosed proxy to (416) 595-9593.

On the Internet: Go to [www.voteproxyonline.com](http://www.voteproxyonline.com) and follow the instructions.

To be effective, a proxy must be received not later than forty-eight (48) hours (excluding Saturdays, Sundays and holidays) prior to the time set for the Meeting or any adjournment thereof.

*Non-registered holders:* Shareholders who wish to appoint a third-party proxyholder to represent them at the virtual Meeting **must submit their Proxy or Voting Instruction Form (as applicable, to TSX Trust Company or as per the instructions on the Voting Instruction Form) prior to registering their proxyholder. Registering the proxyholder is an additional step once a shareholder has submitted their Proxy or Voting Instruction Form. Failure to register a duly appointed proxyholder will result in the proxyholder not receiving a control number to participate in the Meeting.** To register a proxyholder, shareholders **MUST** visit [www.voteproxyonline.com](http://www.voteproxyonline.com) by **October 6, 2026, 9:30 a.m. (MST)** and provide TSX Trust Company with their proxyholder's contact information, so that TSX Trust Company may provide the proxyholder with a control number via email. **Without a control number, proxyholders will not be able to vote at the Meeting.** Guests, including non-registered (beneficial) shareholders who have not duly appointed themselves as proxyholder, can login to the Meeting by clicking "I am a guest" and completing the online registration form. Guests will be able to listen to the Meeting but will not be able to vote or ask questions at the Meeting.

*Voting at the Virtual Meeting:* Registered shareholders and duly appointed proxyholders (including non-registered (beneficial) shareholders who have duly appointed themselves as proxyholder) will be able to attend, vote and ask questions at the Meeting online at <https://virtual-meetings.tsxtrust.com/1978>. Such persons may enter the Meeting by clicking "I have a control number" and entering a valid control number or meeting access number and the case sensitive password: pharmacorp2026.

- **Registered shareholders:** The control number located on the proxy form or in the email notification you received is your control number. If you are a registered shareholder and choose to vote online at the Meeting, you do not need to complete or return your proxy form. You can login to the Meeting and complete a ballot online during the Meeting.
- **Duly appointed proxyholders:** TSX Trust Company will provide the proxyholder (including non-registered (beneficial) shareholders who have duly appointed themselves as proxyholder) with a meeting access number by email after the proxy voting deadline has passed and the proxyholder has been duly appointed AND registered as described above.

Dated at Regina, Saskatchewan, this 25<sup>th</sup> day of August, 2026.

### BY ORDER OF THE BOARD

*signed "Alan Simpson"*

---

Alan Simpson, Executive Chairperson and Director  
PharmaCorp Rx Inc.